United States · FDA National Drug Code directory
EMRELIS
A source-listed medicine record.
Factual source checks only. This page is not a clinically reviewed monograph. Historical or discontinued records may be included; listing does not confirm approval, current availability or pharmacy stock.
Medicine identity
- Source reference
- 0074-1044_998985bb-7cd1-4e80-bd08-8fc7c503f982
- Product NDC
- 0074-1044
- Form
- INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION
- Composition / generic term
- Telisotuzumab Vedotin
- Labeler
- AbbVie Inc.
- Marketing category
- BLA
- Marketing start / end (source format)
- 20250514
- Source listing expiry
- 20261231
Source-listed ingredients
- TELISOTUZUMAB VEDOTIN — 20 mg/mL
These values do not establish equivalence or a dose recommendation.
Packages
- 1 VIAL, SINGLE-DOSE in 1 CARTON (0074-1044-01) / 1 mL in 1 VIAL, SINGLE-DOSE · 0074-1044-01
Source and coverage
Open FDA National Drug Code directory →
Snapshot retrieved: 2026-09-17. This is the acquisition date, not a medical review date.
Clinical information, images and comparisons appear only when separately reviewed for this record. Coverage may be incomplete. Ask a pharmacist or clinician about your treatment.
Browse United States records →